Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Common Share - Schedule of Potential Common Shares Outstanding Excluded from the Computation of Diluted Net Loss Per Share (Details)

v3.10.0.1
Net Loss Per Common Share - Schedule of Potential Common Shares Outstanding Excluded from the Computation of Diluted Net Loss Per Share (Details) - shares
shares in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Anti-dilutive securities    
Total common stock equivalents (in shares) 102,742 75,598
Shares issuable upon conversion of preferred stock    
Anti-dilutive securities    
Total common stock equivalents (in shares) 48,883 46,057
Restricted stock units    
Anti-dilutive securities    
Total common stock equivalents (in shares) 25,614 20,990
Shares issuable upon conversion of 2023 Notes    
Anti-dilutive securities    
Total common stock equivalents (in shares) 20,154 0
Options to purchase common stock    
Anti-dilutive securities    
Total common stock equivalents (in shares) 6,368 6,206
Performance awards    
Anti-dilutive securities    
Total common stock equivalents (in shares) 875 1,486
Shares issuable pursuant to the ESPP    
Anti-dilutive securities    
Total common stock equivalents (in shares) 848 859